These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 37107587)

  • 1. SODD Promotes Lung Cancer Tumorigenesis by Activating the PDK1/AKT and RAF/MEK/ERK Signaling.
    Bao F; An S; Yang Y; Xu TR
    Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxysafflor yellow A inhibited lipopolysaccharide-induced non-small cell lung cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT/mTOR and ERK/MAPK signaling pathways.
    Jiang M; Zhou LY; Xu N; An Q
    Thorac Cancer; 2019 Jun; 10(6):1319-1333. PubMed ID: 31055884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.
    Aksamitiene E; Kholodenko BN; Kolch W; Hoek JB; Kiyatkin A
    Cell Signal; 2010 Sep; 22(9):1369-78. PubMed ID: 20471474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencer of death domains (SODD) inhibits skeletal muscle and kidney enriched inositol 5-phosphatase (SKIP) and regulates phosphoinositide 3-kinase (PI3K)/Akt signaling to the actin cytoskeleton.
    Rahman P; Huysmans RD; Wiradjaja F; Gurung R; Ooms LM; Sheffield DA; Dyson JM; Layton MJ; Sriratana A; Takada H; Tiganis T; Mitchell CA
    J Biol Chem; 2011 Aug; 286(34):29758-70. PubMed ID: 21712384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GINS2 facilitates epithelial-to-mesenchymal transition in non-small-cell lung cancer through modulating PI3K/Akt and MEK/ERK signaling.
    Liu X; Sun L; Zhang S; Zhang S; Li W
    J Cell Physiol; 2020 Nov; 235(11):7747-7756. PubMed ID: 31681988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ponatinib inhibits the proliferation of SNU-449 human hepatocellular cancer cells and blocks MAPK and PDK1/AKT/mTOR signaling pathways].
    Liu C; Pei J; Mu X; Yu B; Gong T; Liang W
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 May; 38(5):425-431. PubMed ID: 35603651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
    Wang Z; Qu L; Deng B; Sun X; Wu S; Liao J; Fan J; Peng Z
    Sci Rep; 2016 Sep; 6():33205. PubMed ID: 27628214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
    Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
    Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGF/EGFR Promotes Salivary Adenoid Cystic Carcinoma Cell Malignant Neural Invasion
    Ren Y; Hong Y; He W; Liu Y; Chen W; Wen S; Sun M
    Curr Cancer Drug Targets; 2022; 22(7):603-616. PubMed ID: 35410600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs.
    Steelman LS; Abrams SL; Shelton JG; Chappell WH; Bäsecke J; Stivala F; Donia M; Nicoletti F; Libra M; Martelli AM; McCubrey JA
    Cell Cycle; 2010 Apr; 9(8):1629-38. PubMed ID: 20372086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RUNX2 Plays An Oncogenic Role in Esophageal Carcinoma by Activating the PI3K/AKT and ERK Signaling Pathways.
    Lu H; Jiang T; Ren K; Li ZL; Ren J; Wu G; Han X
    Cell Physiol Biochem; 2018; 49(1):217-225. PubMed ID: 30138923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
    Gao BB; Wang SX
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-592 Promotes Gastric Cancer Proliferation, Migration, and Invasion Through the PI3K/AKT and MAPK/ERK Signaling Pathways by Targeting Spry2.
    He Y; Ge Y; Jiang M; Zhou J; Luo D; Fan H; Shi L; Lin L; Yang L
    Cell Physiol Biochem; 2018; 47(4):1465-1481. PubMed ID: 29949784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study on the Role and Mechanism of METTL3 Mediating the Up-regulation of 
m6A Modified Long Non-coding RNA THAP7-AS1 in Promoting the Occurrence of 
Lung Cancer].
    Zhang Y; Wang Y; Liu M
    Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):919-933. PubMed ID: 38163978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
    Zhou Y; Li S; Li J; Wang D; Li Q
    Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Ferulic Acid Derivative FXS-3 Inhibits Proliferation and Metastasis of Human Lung Cancer A549 Cells via Positive JNK Signaling Pathway and Negative ERK/p38, AKT/mTOR and MEK/ERK Signaling Pathways.
    Yue SJ; Zhang PX; Zhu Y; Li NG; Chen YY; Li JJ; Zhang S; Jin RY; Yan H; Shi XQ; Tang YP; Duan JA
    Molecules; 2019 Jun; 24(11):. PubMed ID: 31181779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Berberine targets KIF20A and CCNE2 to inhibit the progression of nonsmall cell lung cancer via the PI3K/AKT pathway.
    Wang Q; Wu H; Wu Q; Zhong S
    Drug Dev Res; 2023 Aug; 84(5):907-921. PubMed ID: 37070571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IRS4 promotes the progression of non-small cell lung cancer and confers resistance to EGFR-TKI through the activation of PI3K/Akt and Ras-MAPK pathways.
    Hao P; Huang Y; Peng J; Yu J; Guo X; Bao F; Dian Z; An S; Xu TR
    Exp Cell Res; 2021 Jun; 403(2):112615. PubMed ID: 33894221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
    Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
    Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.